Enzo Biochem appointed Carl Balezentis as president of Enzo Life Sciences, its wholly owned subsidiary, the company said last week.
Formerly, Balezentis was chief executive officer of Lark Technologies prior to its acquisition by Genaissance Pharmaceuticals. After the acquisition, he joined Genaissance as a senior vice-president. Prior to Lark, he was director of business development at Sigma-Aldrich's life sciences division. He was vice president of sales and marketing at Genosys Biotechnologies prior to its acquisition by Sigma-Aldrich.
Balezentis was a director of marketing at Perceptive Scientific Instruments before its acquisition by International Remote Imaging Systems, and a group leader for human identity products at Applied Biosystems.
Orion Genomics co-founder Rob Martienssen has been appointed a fellow of the Royal Society of London, Orion said this week.
Past fellows include Isaac Newton, Charles Darwin, Albert Einstein, and James Watson, Orion said. Watson, like Martienssen, is also a member of Orion's scientific advisory board.
Martienssen holds a BA in natural sciences from Cambridge University and a PhD from the Plant Breeding Institute and Cambridge University.
He currently serves on the faculty at Cold Spring Harbor Laboratory.